TB-500 vs MOTS-c
Both compounds are bioactive peptides with expanding preclinical literatures, but the biological questions they address are distinct. TB-500 has been investigated for actin-cytoskeleton modulation and cell-migration kinetics. MOTS-c has been investigated for AMPK-pathway activation and metabolic homeostasis. This page summarises the published research distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | 17-residue synthetic fragment of thymosin β4 | 16-residue peptide encoded within the mitochondrial 12S rRNA gene |
| Best-studied mechanism | G-actin sequestration; cell-migration kinetics; integrin-linked kinase | AMPK pathway activation; nuclear translocation; metabolic-stress transcriptome regulation |
| Primary research domain | Cardiac repair, corneal healing, dermal regeneration, angiogenesis | Metabolic homeostasis, insulin resistance, exercise physiology |
| Origin | Synthetic fragment of endogenous thymosin beta 4 | Endogenous mitochondrial-derived peptide |
| Common research routes | Intramuscular, subcutaneous | Subcutaneous, intraperitoneal |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
TB-500 acts through the conserved actin-binding motif of thymosin beta 4, sequestering monomeric G-actin and modulating the G-actin/F-actin equilibrium. Downstream effects include altered cell-migration kinetics, integrin-linked kinase activation, and cardiac cell survival. The published literature covers cardiac repair, corneal wound healing, and dermal regeneration.
MOTS-c activates the AMPK pathway and translocates to the nucleus under metabolic stress conditions. The downstream effects include regulation of the nuclear transcriptome, enhanced metabolic homeostasis, improved insulin sensitivity, and exercise-capacity modulation. The peptide’s mitochondrial origin provides a distinct biological context.
The pathways are mechanistically unrelated. TB-500 operates through cytoskeletal dynamics and cell-migration biology. MOTS-c operates through metabolic-stress sensing and AMPK-mediated transcriptional regulation. The research communities and model systems are distinct.
How research has examined each
The TB-500/thymosin beta 4 literature includes cardiac-repair studies (Bock-Marquette, Nature 2004), corneal wound healing (Sosne), dermal healing (Kleinman), and angiogenesis in limb-ischemia models. The evidence base extends from the 1990s through ongoing work on kidney-disease models and transplanted-fat survival.
The MOTS-c literature spans metabolic homeostasis (Lee et al., 2015), nuclear translocation (Kim et al., 2018), exercise physiology, gestational diabetes, neuropathic pain, cardiovascular endpoints, and radiation-protection contexts. The literature has expanded rapidly across multiple organ systems.
The two compounds share the bioactive-peptide research category but not any specific research community, model system, or mechanistic target. Researchers reading both are covering different biological questions.
Stacking considerations in research contexts
Combined administration is not described in the published literature. The mechanisms (cytoskeletal modulation versus AMPK activation) do not overlap, so no pharmacological collision is anticipated. Both compounds are sold as 10 mg lyophilised vials in the Ronin catalog.
Sourcing both at Ronin
Both compounds ship as 10 mg lyophilised peptide in glass vials with certificate-of-analysis documentation. The TB-500 vial page and the MOTS-c vial page carry per-compound spec sheets. Both are research-grade reagents.
Frequently asked research questions
Are TB-500 and MOTS-c related?
No. TB-500 corresponds to the active region of thymosin beta 4 (actin-binding). MOTS-c is an endogenous mitochondrial-derived peptide (AMPK-activating). Different origins and mechanisms.
Do they target overlapping pathways?
No. Cytoskeletal modulation versus AMPK-mediated metabolic signalling.
Are they co-administered?
Not in published research.
Do they share storage practice?
Yes. Both are lyophilised, reconstituted in bacteriostatic water, stored at 2-8 degrees Celsius.
Are either approved?
Neither is FDA or Health Canada approved. Both are research-grade reagents.
References
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature, 2004. [PMID 15565145]
- Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism, 2015. [PMID 25738459]
- Kleinman HK et al. Thymosin beta4 promotes dermal healing. Vitamins and Hormones, 2016. [PMID 27450738]
- Kim KH et al. MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metabolism, 2018. [PMID 29983246]
- Wan W et al. MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023. [PMID 36670507]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.